Monthly Archives: December 2014

E

My recent articles on security here at TalkMarkets have been designed to warn investors about the growing cyber security threat. I continue to illuminate the issue because I know the potential for not doing so can lead to a lot of market pain for companies and individuals alike. So we press on with the latest…

5 Things To Ponder: Unstoppable Force Paradox

As we enter the final month of the year, the markets advance got me thinking about something known as the “Unstoppable Force Paradox.” While you may not be familiar with the name, you will certainly know the definition which questions “What happens when an unstoppable force meets an immovable object?” Even Frank Sinatra sang about it in “Something’s Gotta…

The Big Four Economic Indicators: Nonfarm Employment

Note from dshort: I’ve updated this analysis to include today’s release of the November Employment Report. Official recession calls are the responsibility of the NBER Business Cycle Dating Committee, which is understandably vague about the specific indicators on which they base their decisions. This committee statement is about as close as they get to identifying their method. There…

Smith & Wesson Beats Q2 Earnings Estimates, Cuts Outlook

Smith & Wesson Holding Corp. (SWHC – Snapshot Report) reported second-quarter fiscal 2015 (ending Oct 31, 2014) earnings from continuing operations of 9 cents per share, beating the Zacks Consensus Estimate by 2 cents. The number was, however, lower than the year-ago earnings of 28 cents per share as sales remained weak. Smith & Wesson Holding Corporation –…

Europe (In 2 Ridiculous Charts)

Consider: European stocks just closed at their highest since Jan 2008; Spanish bond yields hit a record low 1.803% and Spanish youth unemployment hovers near a record high 53.8%; Italian bond yields hit a record low 1.72% and Italian youth unemployment is at a record 43.3%. So once again we ask, why exactly does Europe need…

E

Amgen (AMGN) reported on December 3, 2014 that the FDA has approved their Leukemia drug Blincyto (blinatumomab) for the treatment of Philadelphia Chromosome-negative  Relapsed or Refractory B-cell precursor Acute Lymphoblastic Leukemia. This disease is an uncommon form of blood cancer where patients had few or no treatment options. With the approval of Blincyto patients now…